Buy Vocabria (cabotegravir)

What is Vocabria (cabotegravir) for?

Vocabria (cabotegravir) is a prescription medicine ​​used together with the medicine rilpivirine to treat adults with human immunodeficiency virus type 1 (HIV-1) infection. It is used in people who are currently being treated with antiretroviral medicines.^[1]

It is available as a vial of cabotegravir suspension and a vial of rilpivirine suspension (400/600mg or 600/900mg).^[1]

How does Vocabria (cabotegravir) work?

The active ingredient in Vocabria, cabotegravir, is an integrase inhibitor. It can block an enzyme called integrase, which the virus uses to replicate in the body. By blocking integrase, cabotegravir lowers the number of HIV particles in the blood and keeps the levels low.1,2

The medicine cannot cure HIV infection or AIDS, but it can allow the immune system to repair itself and prevent further damage.1,2

Where has Vocabria (cabotegravir) been approved?

Vocabria (cabotegravir) was approved for the treatment of people with HIV-1 infection by:

• Health Canada on September 23, 2020.^[3]
• European Medicines Agency (EMA) on December 17, 2020.^[1]
• The Food and Drug Administration (FDA), USA on January 21, 2021.^[4]
• Therapeutic Goods Administration (TGA), Australia on February 10, 2021.^[5]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Vocabria (cabotegravir) taken?

The standard dosage is:^[1]

• One 30-mg tablet of Vocabria (cabotegravir) together with one 25-mg tablet of Edurant (rilpivirine) taken daily for one month
• After that, Vocabria and rilpivirine injections are given monthly or every 2 months. The first injections are given on the same day as the final dose of the tablets.

Tablets are taken with or without food.^[1]

Vocabria (cabotegravir) may affect the way other medicines work, and other medicines may affect how this medicine works, so it is important that you inform your doctor about all medicines you take.^[1]

Warning: Vocabria (cabotegravir) should not be used with carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for epilepsy) or with rifampicin, rifapentine (antibiotics), because these medicines may reduce the effectiveness of Vocabria.^[1]

Complete information about Vocabria (cabotegravir) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Vocabria (cabotegravir)?

Common adverse reactions

The most common side effects (≥10% of patients) listed in the prescribing information include:^[1]

• Headache
• Nausea
• Abnormal dreams
• Anxiety
• Insomnia

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Allergic reactions
• Liver problems
• Depression or mood changes

Use in a specific population

It is not known if Vocabria (cabotegravir) can harm a fetus. Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding.^[1]

Mothers with a HIV-1 infection should not breastfeed, because the virus can pass to the baby via the breast milk. It is not known if the medicine can pass on to the baby via breast milk and hard a fetus.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [EMA]: Vocabria (cabotegravir) [PDF]
ViiV Healthcare, Dec 2020

2. Cabotegravir (Vocabria) & rilpivirine (Rekambys) injections
Aidsmap.com, Jan 2021

3. ViiV Healthcare Announces Availability of CABENUVA and VOCABRIA in Canada
ViiV Healthcare, Sept 2020

4. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection
FDA press release, Jan 2021

5. Vocabria
TGA, cited Aug 2021